ArriVent BioPharma, Inc. Liquidation Value
AVBP
Other
Cash & Equivalents
$45.54M
As of 2025-12-31
Current Price: N/A
Key Metrics
Cash Liquidation Value
Cash minus Total Obligations
Cash: $45.54M
Total Obligations: -$25.96M
$19.58M
Per share: $0.46
Period: 2025-12-31
Liquid Liquidation Value
Cash + AR minus Total Obligations
Cash: $45.54M
AR: $0
Total Obligations: -$25.96M
$19.58M
Per share: $0.46
Period: 2025-12-31
Operating Liquidation Value
Cash + AR + Inventory minus Total Obligations
Cash: $45.54M
AR: $0
Inventory: $0
Total Obligations: -$25.96M
$19.58M
Per share: $0.46
Period: 2025-12-31
Build your own liquidation scenario
Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.
Liquidation Ladder
| Metric | Total | Per Share |
|---|---|---|
| Cash Liquidation Value | $19.58M | $0.46 |
| Liquid Liquidation Value | $19.58M | $0.46 |
| Operating Liquidation Value | $19.58M | $0.46 |
Key Components (as of 2025-12-31)
| Cash & Equivalents | $45.54M |
| Accounts Receivable | N/A |
| Inventory | N/A |
| Current Liabilities | $25.95M |
| Long-term Debt | N/A |
| Op. Lease Liability | $14,000 |
| Finance Lease | N/A |
| Shares Outstanding | 42.5M |
Explore all 129 XBRL tags and build your own scenario → Open Calculator
Historical
| Period | Cash | AR | Inventory | AP | Curr Liab | LT Debt | Op Lease | Fin Lease |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $45.54M | N/A | N/A | $5.93M | $25.95M | N/A | $14,000 | N/A |
| 2025-09-30 | $112.67M | N/A | N/A | $5.93M | $21.56M | N/A | $56,000 | N/A |
| 2025-06-30 | $112.77M | N/A | N/A | $4.06M | $19.64M | N/A | $98,000 | N/A |
| 2025-03-31 | $49.87M | N/A | N/A | $4.36M | $12.95M | N/A | $138,000 | N/A |
| 2024-12-31 | $74.29M | N/A | N/A | $3.78M | $17.27M | N/A | $176,000 | N/A |
| 2024-09-30 | $282.86M | N/A | N/A | $4.65M | $15.16M | N/A | $213,000 | N/A |
| 2024-06-30 | $298.67M | N/A | N/A | $3.81M | $12.10M | N/A | $250,000 | N/A |
| 2024-03-31 | $317.39M | N/A | N/A | $4.10M | $9.98M | N/A | $285,000 | N/A |
▼ Community Notes